SCHEMBL2272938

SCHEMBL2272938

COc1ccc(S(=O)(=O)n2ccc3cc(Br)ccc32)cc1NC1CCN(C)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.66
CYP3A4 P08684 5/20 0.59
CYP2D6 P10635 4/20 0.59
KCNH2 Q12809 2/20 0.59
DRD2 P14416 2/20 0.59
SLC6A2 P23975 2/20 0.59
HTR2A P28223 2/20 0.59
HTR2C P28335 2/20 0.59
HTR7 P34969 2/20 0.59
HRH1 P35367 2/20 0.59
ADRA1B P35368 2/20 0.59
SLC6A3 Q01959 2/20 0.59
SLC6A4 P31645 1/20 0.59
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2268401 0.90 CYP3A4 (0.60) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2267658 0.89 KCNH2 (0.72) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2266759 0.89 CYP3A4 (0.72) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2268533 0.88 HTR6 (0.54) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2267880 0.88 CYP3A4 (0.60) HTR6CYP3A4CYP2D6KCNH2DRD2
Hydrochloric Acid SCHEMBL2268748 0.87 CYP3A4 (0.59) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2275148 0.86 CYP3A4 (0.56) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL1974004 0.85 HTR6 (0.68) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2268894 0.83 CYP3A4 (0.69) HTR6CYP3A4CYP2D6KCNH2DRD2
SCHEMBL2273734 0.81 HTR6 (0.54) HTR6CYP3A4DRD2HTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998981-B2 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-08-16 US claimed
US-20100168168-A1 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands SUVEN LIFE SCIENCES, LTD. (IN) 2010-07-01 US claimed
EP-1919896-B1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LTD (IN) 2009-12-23 EP claimed
EP-1919896-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. Suven Life Sciences Limited (IN) 2008-05-14 EP claimed
WO-2007020652-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LIMITED (IN) 2007-02-22 WO claimed
US-7998981-B2 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-08-16 US disclosed
US-20100168168-A1 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands SUVEN LIFE SCIENCES, LTD. (IN) 2010-07-01 US disclosed
EP-1919896-B1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LTD (IN) 2009-12-23 EP disclosed
EP-1919896-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. Suven Life Sciences Limited (IN) 2008-05-14 EP disclosed
WO-2007020652-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LIMITED (IN) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168168-A1 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands HTR6, HTR5A, HTR3B HTR6 1/4885CYP3A4 478/4885CYP2D6 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.